Literature Review: Application Lyotropic Liquid Crystals in Topical and Transdermal Drug Delivery Systems
Keywords:
Liquid Crystal, Lyotropic, Lipid Phase
Abstract
This review article discusses the composition, formula, characterization, lyotropic liquid crystals which are formulated in topical and transdermal preparations with different liquid crystal phase carriers. Lyotropic liquid crystals have considerable potential in drug delivery systems. Lyotropic liquid crystals can be characterized by polarized light microscopy (PLM), small-angle X-ray scattering (SAXS), atomic force microscopy (AFM), thermogram electron microscopy (TEM), particle size, viscosity, drug release studies, drug permeation studies. . The formation of liquid crystals can be ascertained by observing birefringence using PLM or SAXS. This review also focuses on the structural classification of lyotropic liquid crystals into cubic, lamellar, and hexagonal phases. The structure of these phases is affected by the addition of surfactants, which include a variety of non-toxic, biodegradable lipids and also enhance drug solubility, drug permeation, bioavailability, and drug efficacy.
References
DAFTAR PUSTAKA
[1] Hitesh J, Rushikesh G, Gauri J, Jagruti M, Nirali T. Liquid crystal as accelerant in drug absorption from topical formulations. Int Res J Pharm, 2(4):86–89, 2011.
[2] Azmi, I.D.M.; Moghimi, S.M.; Yaghmur, A. Cubosomes and hexosomes as versatile platforms for drug delivery. Ther. Deliv. 6, 1347–1364, 2015 [CrossRef] [PubMed]
[3] Mulet, X.; Boyd, B.J.; Drummond, C.J. Advances in drug delivery and medical imaging using colloidal lyotropic liquid crystalline dispersions. J. Colloid Interface Sci, 393, 1–20, 2013 [CrossRef] [PubMed]
[4] Prajakta, P., Gaikwad & Maya T, Desai. Liquid Crystal Phase Its Pharma Applications, International Journal of Pharma Research and Review, 2 (12), 40-52, 2013.
[5] Yogeshvar T. Liquid crystals: an approach to different state of matter. The Pharma Innovation Journal, 7(6):540-545, 2018.
[6] Ganesh shete, Vibha puri, Arvind K Bansal, “Liquid crystals in pharma”, India’s most comprehensive portal-Pharmabiz, March 25, 2009
[7] Stegemeyer H. Topics in Physical Chemistry Volume 3. New York: Dr. Dietrich Steinkopff Veriag GmbH & Co. KG. 1994.
[8] Yhirayha, et al. Formulation of lyotropic liquid crystal containing mulberry stem extract: influences of formulation ingredients on the formation and the nanostructure. International Journal of Cosmetic Science, 36:213-220, 2014.
[9] Rajak P., Nath L.K. dan Bhuyan B. Liquid crystals: An approach in drug delivery. Indian Journal of Pharmaceutical Sciences. 81(1), pp. 11–23, 2019.
[10] Guo C, Wang J, Cao F, Lee RJ, Zhai G. Lyotropic liquid crystal systems in drug delivery. Drug Discov Today, 15(23–24):1032–1040, 2010.
[11] Nagarajan R, Ruckenstein E. Critical micelle concentration: a transition point for micellar size distribution. J Colloid Interface Sci, 60(2):221–231, 1977.
[12] Spicer PT, Hayden KL, Lynch ML, Ofori-Boateng A, Burns JL. Novel process for producing cubic liquid crystalline nanoparticles (cubosomes). Langmuir, 17(19):5748–575, 2001.
[13] Lai J, Lu Y, Yin Z, Hu F, Wu W. Pharmacokinetics and enhanced oral bioavailability in beagle dogs of cyclosporine A encapsulated in glyceryl monooleate/poloxamer 407 cubic nanoparticles. Int J Nanomedicine, 5(1):13–23, 2010.
[14] Boyd BJ, Whittaker DV, Khoo S-M, Davey G. Hexosomes formed from glycerate surfactants – formulation as a colloidal carrier for irinotecan. Int J Pharm., 318(1–2):154–162, 2006.
[15] Lai J, Chen J, Lu Y, et al. Glyceryl monooleate/poloxamer 407 cubic nanoparticles as oral drug delivery systems: I. In vitro evaluation and enhanced oral bioavailability of the poorly water-soluble drug simvastatin. AAPS PharmSciTech, 10(3):960–966, 2009.
[16] Thapa RK, Baskaran R, Madheswaran T, Kim JO, Yong CS, Yoo BK. In vitro release and skin permeation of tacrolimus from monooleinbased liquid crystalline nanoparticles. J Drug Deliv Sci Technol, 22(6):479–484, 2012.
[17] Liu Y, Friberg SE. Role of liquid crystal in the emulsification of a gel emulsion with high internal phase fraction. J Colloid Interface Sci, 340(2):261–268, 2009.
[18] Rajabalaya R, Musa M.N, Kifli N, S.R. Oral and transdermal drug delivery systems: role of lipid-based lyotropic liquid crystals. Drug Design, Development and Therapy, 11 393–406, 2017.
[19] Muller-Goymann CC. Physicochemical characterization of colloidal drug delivery systems such as reverse micelles, vesicles, liquid crystals and nanoparticles for topical administration. Eur J Pharm Biopharm, 58(2):343–356, 2004.
[20] Chang CM, Bodmeier R. Low viscosity monoglyceride-based drug delivery systems transforming into a highly viscous cubic phase. Int J Pharm, 173(1–2):51–60, 1998.
[21] Rosevear FB. Liquid crystals: the mesomorphic phases of surfactant compositions. J Soc Cosmet Chem, 19:581–594, 1968.
[22] Boyd BJ, Whittaker DV, Khoo S-M, Davey G. Lyotropic liquid crystalline phases formed from glycerate surfactants as sustained release drug delivery systems. Int J Pharm., 309(1–2):218–226, 2006.
[23] Bender J, Jarvoll P, Nyden M, Engstrom S. Structure and dynamics of a sponge phase in the methyl delta-aminolevulinate/monoolein/water/propylene glycol system. J Colloid Interface Sci, 317(2):577– 584, 2008.
[24] Chen Y, Lu Y, Zhong Y, Wang Q, Wu W, Gao S. Ocular delivery of cyclosporine A based on glyceryl monooleate/poloxamer 407 liquid crystalline nanoparticles: preparation, characterization, in vitro corneal penetration and ocular irritation. J Drug Target, 20(10): 856–863, 2012.
[25] Sikora A. Utilization of various atomic force microscopy techniques in investigation of liquid crystal compounds. In: Iwan A, Schab-Balcerzak E, editors. Liquid Crystalline Organic Compounds and Polymers as Materials of the XXI Century: From Synthesis to Applications. Trivandrum: Transworld Research Network, 191–219, 2011.
[26] Neto C, Aloisi G, Baglioni P. Imaging soft matter with the atomic force microscope: cubosomes and hexosomes. J Phys Chem B, 103(19): 3896–3899, 1999.
[27] Omray LK. Liquid crystals as novel vesicular delivery system: a review. Curr Trends Technol Sci., 2(6):347–353, 2013.
[28] de Carvalho Vicentini, F.T.M.; Depieri, L.V.; Polizello, A.C.M.; Del Ciampo, J.O.; Spadaro, A.C.C.; Fantini, M.C.A.; Vitória Lopes Badra Bentley, M. Liquid crystalline phase nanodispersions enable skin delivery of siRNA. Eur. J. Pharm. Biopharm, 83, 16–24, 2013. [CrossRef] [PubMed]
[29] Estracanholli, E.A.; Praça, F.S.G.; Cintra, A.B.; Pierre, M.B.R.; Lara, M.G. Liquid crystalline systems for transdermal delivery of celecoxib: In Vitro drug release and skin permeation studies. AAPS PharmSciTech, 15, 1468–1475, 2014. [CrossRef]
[30] Luo M, Shen Q, Chen J. Transdermal delivery of paeonol using cubic gel and microemulsion gel. Int J Nanomedicine, 6:1603–1610, 2011.
[31] Nesseem DI. Formulation and evaluation of itraconazole via liquid crystal for topical delivery system. J Pharm Biomed Anal, 26(3): 387–399, 2001.
[32] Lopes LB, Speretta FFF, Bentley MVLB. Enhancement of skin penetration of vitamin K using monoolein-based liquid crystalline systems. Eur J Pharm Sci, 32(3):209–215, 2007.
[33] Dante, M, de, C, L., Cardose, L, N, B., Fantini, M, C, de, A., Praca, F, S, G., Medina, W, S, G., Pierre, M, B, R., dan Lara, M, G. Liquid Crystalline Systems Based on Glyceryl Monooleate and Penetration Enhancers for Skin Delivery of Celecoxib: Characterization, In Vitro Drug Release, and In Vivo Studies. Journal of Pharmaceutical Sciences xxx 1-9, 2017.
[34] Milak S., Chemelli A., Glatter O dan Zimmer A. Vancomycin Loaded Glycerol Monooleate Liquid Crystalline Phases Modified with Surfactants. Pharmaceutics, 12, 521, 2020.
[35] Cohen-Avrahami, M. et al. HII mesophase and peptide cell-penetrating enhancers for improved transdermal delivery of sodium diclofenac. Colloid Surf. B, 77, 131–138, 2010.
[36] Esposito, E. et al. Cubosome dispersions as delivery systems for percutaneous administration of indomethacin. Pharm. Res, 22, 2163–2173, 2005.
[37] Bender, J. et al. Lipid cubic phases for improved topical drug delivery in photodynamic therapy. J. Control. Release, 106, 350–360, 2005.
[38] Shah MH, Paradkar A. Effect of HLB of additives on the properties and drug release from the glyceryl monooleate matrices. Eur J Pharm Biopharm, 67: 166-174, 2007.
[1] Hitesh J, Rushikesh G, Gauri J, Jagruti M, Nirali T. Liquid crystal as accelerant in drug absorption from topical formulations. Int Res J Pharm, 2(4):86–89, 2011.
[2] Azmi, I.D.M.; Moghimi, S.M.; Yaghmur, A. Cubosomes and hexosomes as versatile platforms for drug delivery. Ther. Deliv. 6, 1347–1364, 2015 [CrossRef] [PubMed]
[3] Mulet, X.; Boyd, B.J.; Drummond, C.J. Advances in drug delivery and medical imaging using colloidal lyotropic liquid crystalline dispersions. J. Colloid Interface Sci, 393, 1–20, 2013 [CrossRef] [PubMed]
[4] Prajakta, P., Gaikwad & Maya T, Desai. Liquid Crystal Phase Its Pharma Applications, International Journal of Pharma Research and Review, 2 (12), 40-52, 2013.
[5] Yogeshvar T. Liquid crystals: an approach to different state of matter. The Pharma Innovation Journal, 7(6):540-545, 2018.
[6] Ganesh shete, Vibha puri, Arvind K Bansal, “Liquid crystals in pharma”, India’s most comprehensive portal-Pharmabiz, March 25, 2009
[7] Stegemeyer H. Topics in Physical Chemistry Volume 3. New York: Dr. Dietrich Steinkopff Veriag GmbH & Co. KG. 1994.
[8] Yhirayha, et al. Formulation of lyotropic liquid crystal containing mulberry stem extract: influences of formulation ingredients on the formation and the nanostructure. International Journal of Cosmetic Science, 36:213-220, 2014.
[9] Rajak P., Nath L.K. dan Bhuyan B. Liquid crystals: An approach in drug delivery. Indian Journal of Pharmaceutical Sciences. 81(1), pp. 11–23, 2019.
[10] Guo C, Wang J, Cao F, Lee RJ, Zhai G. Lyotropic liquid crystal systems in drug delivery. Drug Discov Today, 15(23–24):1032–1040, 2010.
[11] Nagarajan R, Ruckenstein E. Critical micelle concentration: a transition point for micellar size distribution. J Colloid Interface Sci, 60(2):221–231, 1977.
[12] Spicer PT, Hayden KL, Lynch ML, Ofori-Boateng A, Burns JL. Novel process for producing cubic liquid crystalline nanoparticles (cubosomes). Langmuir, 17(19):5748–575, 2001.
[13] Lai J, Lu Y, Yin Z, Hu F, Wu W. Pharmacokinetics and enhanced oral bioavailability in beagle dogs of cyclosporine A encapsulated in glyceryl monooleate/poloxamer 407 cubic nanoparticles. Int J Nanomedicine, 5(1):13–23, 2010.
[14] Boyd BJ, Whittaker DV, Khoo S-M, Davey G. Hexosomes formed from glycerate surfactants – formulation as a colloidal carrier for irinotecan. Int J Pharm., 318(1–2):154–162, 2006.
[15] Lai J, Chen J, Lu Y, et al. Glyceryl monooleate/poloxamer 407 cubic nanoparticles as oral drug delivery systems: I. In vitro evaluation and enhanced oral bioavailability of the poorly water-soluble drug simvastatin. AAPS PharmSciTech, 10(3):960–966, 2009.
[16] Thapa RK, Baskaran R, Madheswaran T, Kim JO, Yong CS, Yoo BK. In vitro release and skin permeation of tacrolimus from monooleinbased liquid crystalline nanoparticles. J Drug Deliv Sci Technol, 22(6):479–484, 2012.
[17] Liu Y, Friberg SE. Role of liquid crystal in the emulsification of a gel emulsion with high internal phase fraction. J Colloid Interface Sci, 340(2):261–268, 2009.
[18] Rajabalaya R, Musa M.N, Kifli N, S.R. Oral and transdermal drug delivery systems: role of lipid-based lyotropic liquid crystals. Drug Design, Development and Therapy, 11 393–406, 2017.
[19] Muller-Goymann CC. Physicochemical characterization of colloidal drug delivery systems such as reverse micelles, vesicles, liquid crystals and nanoparticles for topical administration. Eur J Pharm Biopharm, 58(2):343–356, 2004.
[20] Chang CM, Bodmeier R. Low viscosity monoglyceride-based drug delivery systems transforming into a highly viscous cubic phase. Int J Pharm, 173(1–2):51–60, 1998.
[21] Rosevear FB. Liquid crystals: the mesomorphic phases of surfactant compositions. J Soc Cosmet Chem, 19:581–594, 1968.
[22] Boyd BJ, Whittaker DV, Khoo S-M, Davey G. Lyotropic liquid crystalline phases formed from glycerate surfactants as sustained release drug delivery systems. Int J Pharm., 309(1–2):218–226, 2006.
[23] Bender J, Jarvoll P, Nyden M, Engstrom S. Structure and dynamics of a sponge phase in the methyl delta-aminolevulinate/monoolein/water/propylene glycol system. J Colloid Interface Sci, 317(2):577– 584, 2008.
[24] Chen Y, Lu Y, Zhong Y, Wang Q, Wu W, Gao S. Ocular delivery of cyclosporine A based on glyceryl monooleate/poloxamer 407 liquid crystalline nanoparticles: preparation, characterization, in vitro corneal penetration and ocular irritation. J Drug Target, 20(10): 856–863, 2012.
[25] Sikora A. Utilization of various atomic force microscopy techniques in investigation of liquid crystal compounds. In: Iwan A, Schab-Balcerzak E, editors. Liquid Crystalline Organic Compounds and Polymers as Materials of the XXI Century: From Synthesis to Applications. Trivandrum: Transworld Research Network, 191–219, 2011.
[26] Neto C, Aloisi G, Baglioni P. Imaging soft matter with the atomic force microscope: cubosomes and hexosomes. J Phys Chem B, 103(19): 3896–3899, 1999.
[27] Omray LK. Liquid crystals as novel vesicular delivery system: a review. Curr Trends Technol Sci., 2(6):347–353, 2013.
[28] de Carvalho Vicentini, F.T.M.; Depieri, L.V.; Polizello, A.C.M.; Del Ciampo, J.O.; Spadaro, A.C.C.; Fantini, M.C.A.; Vitória Lopes Badra Bentley, M. Liquid crystalline phase nanodispersions enable skin delivery of siRNA. Eur. J. Pharm. Biopharm, 83, 16–24, 2013. [CrossRef] [PubMed]
[29] Estracanholli, E.A.; Praça, F.S.G.; Cintra, A.B.; Pierre, M.B.R.; Lara, M.G. Liquid crystalline systems for transdermal delivery of celecoxib: In Vitro drug release and skin permeation studies. AAPS PharmSciTech, 15, 1468–1475, 2014. [CrossRef]
[30] Luo M, Shen Q, Chen J. Transdermal delivery of paeonol using cubic gel and microemulsion gel. Int J Nanomedicine, 6:1603–1610, 2011.
[31] Nesseem DI. Formulation and evaluation of itraconazole via liquid crystal for topical delivery system. J Pharm Biomed Anal, 26(3): 387–399, 2001.
[32] Lopes LB, Speretta FFF, Bentley MVLB. Enhancement of skin penetration of vitamin K using monoolein-based liquid crystalline systems. Eur J Pharm Sci, 32(3):209–215, 2007.
[33] Dante, M, de, C, L., Cardose, L, N, B., Fantini, M, C, de, A., Praca, F, S, G., Medina, W, S, G., Pierre, M, B, R., dan Lara, M, G. Liquid Crystalline Systems Based on Glyceryl Monooleate and Penetration Enhancers for Skin Delivery of Celecoxib: Characterization, In Vitro Drug Release, and In Vivo Studies. Journal of Pharmaceutical Sciences xxx 1-9, 2017.
[34] Milak S., Chemelli A., Glatter O dan Zimmer A. Vancomycin Loaded Glycerol Monooleate Liquid Crystalline Phases Modified with Surfactants. Pharmaceutics, 12, 521, 2020.
[35] Cohen-Avrahami, M. et al. HII mesophase and peptide cell-penetrating enhancers for improved transdermal delivery of sodium diclofenac. Colloid Surf. B, 77, 131–138, 2010.
[36] Esposito, E. et al. Cubosome dispersions as delivery systems for percutaneous administration of indomethacin. Pharm. Res, 22, 2163–2173, 2005.
[37] Bender, J. et al. Lipid cubic phases for improved topical drug delivery in photodynamic therapy. J. Control. Release, 106, 350–360, 2005.
[38] Shah MH, Paradkar A. Effect of HLB of additives on the properties and drug release from the glyceryl monooleate matrices. Eur J Pharm Biopharm, 67: 166-174, 2007.
Published
2023-11-24
How to Cite
Rahmadasmi, N., Zaini, E., & Agustin, R. (2023). Literature Review: Application Lyotropic Liquid Crystals in Topical and Transdermal Drug Delivery Systems. JPK : Jurnal Proteksi Kesehatan, 12(2), 121-129. https://doi.org/10.36929/jpk.v12i2.681
Section
Literature Review
